3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
4
CNS
3
Myeloid
2
Lymphoid
2
Genitourinary
2
Gastrointestinal
2
NET
1
Endocrine
1
Conditions
Neuroendocrine Tumors
4
Pheochromocytoma
2
Paraganglioma
2
Thymoma
1
Sarcoma, Synovial
1
Recurrence
1
Osteosarcoma
1
Neuroblastoma
1
Mesothelioma
1
Meningioma
1
Medulloblastoma
1
Glioma
1
Glioblastoma
1
Esthesioneuroblastoma, Olfactory
1
Ependymoma
1
EGFR-Mutated Non-Small-Cell Lung Carcinoma
1
Carcinoid Tumor
1
Adrenal Gland Neoplasms
1
Adrenal Cortex Neoplasms
1
Interventions
Nivolumab
2
tipifarnib
1
olaparib
1
lutetium Lu 177 dotatate
1
fludarabine
1
entinostat
1
cixutumumab
1
cabozantinib
1
aldesleukin
1
Quality of Life
1
Patient Reported Outcome Measures
1
Oxaliplatin
1
Molecular Diagnostic Techniques
1
LY2940680
1
Ipilimumab
1
Immunotherapy
1
Fentanyl
1
Drug Therapy
1
Cyclophosphamide
1
CTLA-4 Antigen
1
Biological Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Osteosarcoma
×
olaparib
×
Endocrine
×
Clear all
NCT06607692
2026-06-04
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled